Nicotinamide Riboside Supplement

## What is nicotinamide riboside? Nicotinamide riboside (NR) is a vitamin B3 precursor that the body converts to NAD+ (nicotinamide adenine dinucleotide), the central electron-carrier coenzyme in cellular metabolism. NR is one of three commercially available NAD+ precursors (alongside NMN and high-dose nicotinamide), and the most-studied of the three in human trials. NR was identified as a NAD+ precursor in the 2000s by the Charles Brenner laboratory at the University of Iowa. The discovery prompted commercialization through Chromadex under the brand name Niagen, with patent protection that has shaped the supplemental NAD+ market significantly. The first human pharmacokinetic trial (Trammell 2016) established that oral NR raises plasma NAD+ within hours and is well-tolerated at doses up to 1,000 mg/day. Subsequent trials have replicated the plasma NAD+ rise across populations and dose ranges. The rationale for raising NAD+ rests on the observation that NAD+ levels decline with age in most tissues, and that this decline contributes to mitochondrial dysfunction, sirtuin inactivation, and the broader cellular phenotype of aging. The hypothesis powered substantial preclinical work showing that NR supplementation reverses aging biomarkers in mice and improves several disease models. The human evidence is more cautious than the supplement marketing implies. Plasma NAD+ rises consistently in trials. Tissue NAD+ rises are inconsistent across trials. Clinical outcomes are concentrated in surrogate biomarkers (insulin sensitivity, blood pressure, inflammatory markers) rather than disease endpoints or longevity markers. Legal status: dietary supplement in the US, EU, Asia. WADA does not list it. ## Mechanism of action NR is converted to NAD+ via the salvage pathway. NR is phosphorylated to NMN by nicotinamide riboside kinase (NRK) enzymes, then NMN is adenylylated to NAD+ by NMNAT enzymes. NRK1 is widely expressed; NRK2 is upregulated under stress. NAD+ is the substrate for several major enzyme systems: - **Sirtuins (SIRT1-7)**: NAD+-dependent deacetylases that regulate metabolism, DNA repair, and mitochondrial biogenesis - **PARPs**: poly-ADP-ribose polymerases consuming NAD+ during DNA damage repair - **CD38**: an ectoenzyme whose expression rises with aging and consumes NAD+ extracellularly The aging-NAD+ decline is thought to result largely from rising CD38 activity rather than declining synthesis, which is one reason adding more precursor may not fully reverse the tissue phenotype. Pharmacokinetics: oral NR raises plasma NAD+ metabolites within 1 to 2 hours; peak at 2 to 6 hours; chronic dosing produces sustained 30 to 60% rises in plasma NAD+ at 250 to 1,000 mg/day. ## Evidence base by outcome ### Plasma NAD+ levels A-tier. Multiple trials including Trammell 2016, Martens 2018, Dollerup 2018, and others reproducibly show 30-60% rises in plasma NAD+ at 250-1,000 mg/day NR. ### Cardiovascular surrogates B-tier. Martens 2018 (n=24 healthy older adults, 500 mg/day for 6 weeks) reported reduced systolic blood pressure (~6 mmHg) and reduced arterial stiffness. The effect size is modest but consistent. ### Insulin sensitivity C-tier. Dollerup 2018 (n=40 obese non-diabetic men, 1,000 mg/day for 12 weeks) reported no significant change in insulin sensitivity despite plasma NAD+ rise. Other trials have shown modest improvements in selected populations. ### Skeletal muscle outcomes C-tier. Trials in Parkinson's disease and aging populations report modest functional improvements; the case is weaker than for NMN. ### Cognitive function C-tier. Small trials in older adults report modest cognitive improvements; effect sizes inconsistent. ### Hard clinical endpoints No trials of NR have measured cardiovascular events, mortality, cancer incidence, or other hard endpoints. The longevity claim rests on mouse data and human surrogate biomarkers. ## Dosage and administration Most-studied dose ranges: - 250 mg/day: starter dose - 500 mg/day: most common in clinical trials (Martens 2018, Dollerup 2018) - 1,000 mg/day: upper dose with consistent safety data Dose-response above 500 mg/day for clinical effect is unclear. Plasma NAD+ rises with higher doses; tissue effects may not. Morning dosing on empty stomach is conventional. With food affects absorption modestly but not dramatically. No cycling required. Cumulative tolerance has not been observed in trials of up to 1 year. Expect plasma NAD+ effects within days. Surrogate biomarker effects (BP, arterial stiffness) take 6 to 12 weeks. Subjective effects are small to absent. ## Side effects and safety Clean safety profile in trials of up to 1 year at doses up to 1,000 mg/day. Reported adverse events are similar to placebo: mild GI upset (less than 10%), occasional headache. Long-term safety data limited beyond 1 year. The biological argument for caution rests on the same NAD+-supports-cellular-proliferation reasoning as NMN; concern is theoretical, not supported by trial data, but not refuted. Drug interactions are minimal at supplement doses. Pregnancy and lactation: precautionary; insufficient supplement-dose data. ## Stack interactions and timing NR pairs in marketing with pterostilbene (Niagen + pterostilbene = Basis by Elysium Health, the original Sinclair-adjacent commercialization). The pterostilbene addition is mechanistically plausible (sirtuin activator) but the comparative trial evidence vs NR alone is limited. NR + TMG (trimethylglycine) combination is mechanistically sensible: NAD+ catabolism produces nicotinamide that requires methylation for excretion, and high-dose NAD+ precursors theoretically deplete methyl groups. Trial evidence absent. NR + NMN combination is sometimes marketed but lacks comparative evidence supporting the combination over either alone. Morning empty-stomach dosing is conventional. Sublingual and liposomal forms are sometimes marketed but lack comparative-superiority evidence. ## Practical notes Quality matters. Niagen by Chromadex is the most-studied branded form; generic NR products vary in actual NR content. Look for products specifying Niagen sourcing or providing third-party Certificate of Analysis. Cost is high. Niagen at 500 mg/day runs roughly 30 to 60 dollars per month. Generic NR is cheaper but quality variable. For users choosing between NR and NMN: NR has the larger human safety database and slightly more PK data. NMN has the more recent commercial momentum and partially overlapping commercial conflict (the FDA dietary-supplement determination affected NMN, not NR, which has shifted some buyers toward NR). Clinical superiority of one over the other is not established. For users wanting NAD+ support cost-effectively: high-dose nicotinamide (the cheap, abundant B3 form) raises NAD+ at much lower cost. The trade-off is theoretical sirtuin inhibition at very high nicotinamide doses, which has driven the consumer market toward NR and NMN. Expect plasma NAD+ effects within days; subjective effects small to absent at typical doses. If the goal is broad longevity protection, the evidence base for omega-3, vitamin D, magnesium, and exercise is substantially stronger than for NR or NMN at current dose levels and trial maturity.